Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Conference Call November 13, 2023 8:00 AM ET
Company Participants
Maria Yonkoski - Investor Relations, ICR
Brian Sullivan - Chief Executive Officer and Co-Founder
Vicky Hahne - Chief Financial Officer
Conference Call Participants
Boris Peaker - Cowen
Gil Blum - Needham & Co.
Alex Nowak - Craig-Hallum
Operator
Greetings, and welcome to the Celcuity Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Maria Yonkoski with ICR. Thank you, ma'am. You may begin.
Maria Yonkoski
Thank you, operator, and good morning to everyone on the call. Thank you for joining us to review Celcuity's third quarter 2023 financial results and business update.
Earlier this morning, Celcuity released financial results for the third quarter ending September 30, 2023. The press release can be found on the Investors section of the website.
Joining me on the call today are Brian Sullivan, Celcuity's Chief Executive Officer and Co-Founder; and Vicki Hahne, Chief Financial Officer.
Before we begin, I would like to remind listeners that our comments today will include some forward-looking statements. These statements involve a number of risks and uncertainties, which are outlined in today's press release and in our reports and filings with the SEC. Actual events or results may differ materially from those projected in the forward-looking statements. Such forward-looking statements and their implications involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected.
On this call, we will also refer to non-GAAP financial measures. These non-GAAP measures are used by management to make strategic decisions, forecast future results and evaluate the company's current performance. Management believes the presentation of these non-GAAP financial measures is useful for investors' understanding and assessment of the company's ongoing core operations and prospects for the future. You can find the table reconciling the non-GAAP financial measures to GAAP measures in today's press release.
And with that, I would now like to turn the call over to Brian Sullivan, CEO of Celcuity. Please go ahead.
Brian Sullivan
Thank you, Maria, and good morning to everyone joining us on today's call.
Our current focus at Celcuity is to develop treatments for patients who have cancers involving the PI3K/mTOR or PAM signaling pathway. The PAM pathway is one of the most important oncogenic pathways. It regulates key metabolic functions, cross regulates other oncogenic pathways and affects the tumor microenvironment, which can directly affect how a patient's immune system responds to a tumor. It is also the most highly mutated by a significant margin of all signaling pathways. 38% of solid tumors have a PAM-related mutation or alteration.